CLAIM #69434 · AbbVie Inc (ABBV) · 2026Q2 earnings call · Jul 31, 2026 · due Jan 31, 2027
“We are very excited about the growth potential in dermatology with vitiligo and alopecia areata now approved in Europe and U.S. approval decisions anticipated over the next few quarters.”
Jeff Stewart · Chief Commercial Officer
PENDING
graded after results covering Jan 31, 2027 are reported
Verify independently
SEC filings for ABBV ↗ · Claim quote is verbatim from the 2026Q2 earnings call.